Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 10/20 | 0.50 |
| ▸ | RARA | P10276 | 9/20 | 0.46 |
| ▸ | RARG | P13631 | 9/20 | 0.46 |
| ▸ | RARB | P10826 | 8/20 | 0.46 |
| ▸ | RXRB | P28702 | 5/20 | 0.41 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.39 |
| ▸ | RXRG | P48443 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10458056 | 0.76 | RXRA (0.56) | RXRARARARARGRARBRXRB | |
| SCHEMBL5360671 | 0.76 | RXRA (0.52) | RXRARARARARGRARBRXRB | |
| SCHEMBL9746853 | 0.71 | RARB (0.65) | RXRARARARARGRARBRXRB | |
| SCHEMBL5356776 | 0.70 | RXRA (0.73) | RXRARARARARGRARBRXRB | |
| SCHEMBL3819800 | 0.68 | RXRA (0.49) | RXRARARARARGRARBRXRB | |
| SCHEMBL10459874 | 0.68 | RXRA (0.64) | RXRARARARARGRARBRXRB | |
| SCHEMBL8458521 | 0.68 | RXRA (0.66) | RXRARARARARGRARBRXRB | |
| SCHEMBL8458523 | 0.68 | RXRA (0.66) | RXRARARARARGRARBRXRB | |
| SCHEMBL3541162 | 0.67 | RXRA (0.58) | RXRARARARARGRARBRXRB | |
| SCHEMBL8458824 | 0.67 | RXRA (1.00) | RXRARARARARGRARBRXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070099991-A1 | SELECTIVE RXR LIGANDS | HAFFNER CURT D | 2007-05-03 | — | — | US | disclosed |
| US-7173134-B2 | Selective RXR ligands | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-06 | — | — | US | disclosed |
| US-20040198980-A1 | Selective rxr ligands | SMITHKLINE BEECHAM CORPORATION | 2004-10-07 | — | — | US | disclosed |
| EP-1430042-A2 | BICYCLIC HETEROCYCLES AS RXR LIGANDS | SmithKline Beecham Corporation (US) | 2004-06-23 | — | — | EP | disclosed |
| WO-2003027090-A2 | BICYCLIC HETEROCYCLES AS RXR LIGANDS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198980-A1 | Selective rxr ligands | RXRA, RXRB, RXRG | RXRA 1/4885RARA 18/4885RARG 24/4885 |
| US-20070099991-A1 | SELECTIVE RXR LIGANDS | RXRB, RXRA, RXRG | RXRA 2/4885RARA 17/4885RARG 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.